Trametinib
- Generic Name
- Trametinib
- Brand Names
- Mekinist, Spexotras
- Drug Type
- Small Molecule
- Chemical Formula
- C26H23FIN5O4
- CAS Number
- 871700-17-3
- Unique Ingredient Identifier
- 33E86K87QN
- Background
Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor. It was first approved by the FDA in May 2013 for the treatment of melanoma. It was later approved by Health Canada on July 18, 2013 and by the European Commission on June 30, 2014. Trametinib is currently approved to treat a variety of c...
- Indication
Trametinib is indicated as monotherapy for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
It is used in combination with dabrafenib for the:
...
- Associated Conditions
- Advanced Non-Small Cell Lung Cancer (NSCLC), Locally Advanced Anaplastic Thyroid Cancer, Low-Grade Glioma, Melanoma, Metastatic Anaplastic Thyroid Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Stage III Melanoma, Unresectable Melanoma, Unresectable or Metastatic Solid Tumors
- Associated Therapies
- -
Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-09-10
- Last Posted Date
- 2014-07-28
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT01938456
A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors
- First Posted Date
- 2013-09-10
- Last Posted Date
- 2019-07-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 34
- Registration Number
- NCT01938443
- Locations
- 🇬🇧
GSK Investigational Site, Newcastle upon Tyne, United Kingdom
Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-09-05
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 26
- Registration Number
- NCT01935973
- Locations
- 🇺🇸
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States
🇺🇸University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)
- First Posted Date
- 2013-08-27
- Last Posted Date
- 2017-07-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT01928940
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2013-07-31
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 16
- Registration Number
- NCT01912625
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2013-07-25
- Last Posted Date
- 2018-04-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT01907815
- Locations
- 🇺🇸
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations
- Conditions
- Interventions
- First Posted Date
- 2013-04-09
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 208
- Registration Number
- NCT01827384
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
- Conditions
- Interventions
- First Posted Date
- 2013-01-14
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 38
- Registration Number
- NCT01767454
- Locations
- 🇺🇸
GSK Investigational Site, Houston, Texas, United States
BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
- Conditions
- Interventions
- First Posted Date
- 2012-12-17
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 166
- Registration Number
- NCT01750918
- Locations
- 🇬🇧
Novartis Investigative Site, Birmingham, United Kingdom
Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer
- First Posted Date
- 2012-12-04
- Last Posted Date
- 2023-09-18
- Target Recruit Count
- 19
- Registration Number
- NCT01740648
- Locations
- 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.